Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A

Oncogene

Volumn 26, Issue 46, 2007, Pages 6593-6603

  Lim, S K ^a   Gopalan, G ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Singapore Health Services   (Singapore)

Author keywords

Antizyme; Aurora A; Degradation; Ubiquitin independent

Indexed keywords

ANTIZYME; ANTIZYME 1; AURORA A KINASE; AURORA A KINASE INTERACTING PROTEIN 1; POLYAMINE; PROTEASOME; REGULATOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ARTICLE; AURORA A ONCOGENE; CARCINOGENESIS; CARCINOMA CELL; CHO CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENE OVEREXPRESSION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; RAT; STEADY STATE;

AMINO ACID SUBSTITUTION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOWN-REGULATION; HELA CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; RETICULOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; UBIQUITIN;

EID: 35348851301     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210482     Document Type: Article

References (43)

1. Asher G, Tsevetkov P, Kahana C, Shaul Y. (2005). A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19: 316-321.
2. Bercovich Z, Rosenberg-Hasson Y, Ciechanover A, Kahana C. (1989). Degradation of ornithine decarboxylase in reticulocyte lysate is ATP-dependent but ubiquitin-independent J. Biol Chem 264: 15949-15952.
3. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B et al. (1998). A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17: 3052-3065.
4. Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, Bearss D et al. (2005). Aurora-A over-expression in highgrade PIN lesions and prostate cancer. Prostate 64: 341-346.
5. Chen H, MacDonald A, Coffino P. (2002). Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase. J Biol Chem 277: 45957-45961.
6. Coffino P. (2001). Regulation of cellular polyamines by antizyme. Nature Rev 2: 188-194.
7. Crane R, Klofper A, Ruderman JV. (2004). Requirements for the destruction of human Aurora-A. J Cell Sci 117: 5975-5983.
8. Feith DJ, Shantz LM, Pegg AE. (2001). Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis. Cancer Res 61: 6073-6081.
9. Fong LY, Feith DJ, Pegg AE. (2003). Antizyme overexpression in transgenic mice reduces cell proliferation, increases apoptosis, and reduces N-nitroso methyl-benzylamine-induced forestomach carcinogenesis. Cancer Res 63: 3945-3954.
10. Gandre S, Bercovich Z, Kahana C. (2002). Ornithine decarboxylase-antizyme is rapidly degraded through a mechanism that requires functional ubiquitin-dependent proteolytic activity. Eur J Biochem 269: 1316-1322.
11. Gardini G, Cravanzola C, Autelli R, Testore G, Cesa R, Morando L et al. (2003). Agmatine inhibits the proliferation of rat hepatoma cells by modulation of polyamine metabolism. J Hepatol 39: 793-799.
12. Gerner EW, Meyskens Jr FL. (2004). Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 781-792.
13. Glass JR, Gerner EW. (1987). Spermidine mediates degradation of ornithine decarboxylase by a non-lysosomal, ubiquitin-independent mechanism. J Cell Physiol 130: 133-141.
14. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA et al. (2003). Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9: 1420-1426.
15. Hoffman DW, Carroll D, Martinez N, Hackert ML. (2005). Solution structure of a conserved domain of antizyme: a protein regulator of polyamines. Biochemistry 44: 11777-11785.
16. Honda K, Mihara H, Kato Y, Yamaguchi A, Tanaka H, Yasuda H et al. (2000). Degradation of human Aurora2 protein kinase by the anaphase-promoting complexubiquitin-proteasome pathway. Oncogene 19: 2812-2819.
17. Ivanov IP, Gesteland RF, Atkins JF. (2000). Antizyme expression: a subversion of triplet decoding, which is remarkably conserved by evolution, is a sensor for an autoregulatory circuit. Nucleic Acid Res 28: 3185-3196.
18. Iwata S, Sato Y, Asada M, Takagi M, Tsujimoto A, Inaba T et al. (1999). Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation. Oncogene 18: 165-172.
19. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. (2003). MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 22: 6365-6377.
20. Kiat LS, Hui KM, Gopalan G. (2002). Aurora-A kinase interacting protein (AIP), a novel negative regulator of human Aurora-A kinase. J Biol Chem 277: 45558-45565.
21. Koike C, Chao DT, Zetter BR. (1999). Sensitivity to polyamineinduced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res 59: 6109-6112.
22. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K et al. (2003). Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9: 991-997.
23. Li X, Coffino P. (1992). Regulated degradation of ornithine decarboxylase requires interaction with the polyamineinducible protein antizyme. Mol Cell Biol 12: 3556-3562.
24. Li X, Coffino P. (1993). Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamineinducible inhibitory protein. Mol Cell Biol 13: 2377-2383.
25. Lim SK, Gopalan G. (2007). Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-a degradation through alternative ubiquitin-independent pathway. Biochem J 403: 119-127.
26. Lin Y, Martin J, Gruendler C, Farley J, Meng X, Li BY et al. (2002). A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol 3: 15.
27. Littlepage LE, Ruderman JV. (2002). Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 16: 2274-2285.
28. Mangold U. (2006). Antizyme inhibitor: mysterious modulator of cell proliferation. Cell Mol Life Sci 63: 2095-2101.
29. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI et al. (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-779.
30. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T et al. (1992). Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360: 597-599.
31. Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M et al. (2004). Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 279: 41504-41511.
32. Rom E, Kahana C. (1994). Polyamines regulate the expression of ornithine decarboxylase antizyme in vitro by inducing ribosomal frame-shifting. Proc Natl Acad Sci USA 91: 3959-3963.
33. Rosenberg-Hasson Y, Bercovich Z, Ciechanover A, Kahana C. (1989). Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent. Eur J Biochem 185: 469-474.
34. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K et al. (2001). Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84: 824-831.
35. Satriano J, Matsufuji S, Murakami Y, Lortie MJ, Schwartz D, Kelly CJ. (1998). Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J Biol Chem 273: 15313-15315.
36. Sdek P, Ying H, Chang DLF, Qiu W, Zheng H, Touitou R et al. (2005). MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699-708.
37. Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL. (1996). The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J 15: 3806-3812.
38. Taguchi S, Honda K, Sugiura K, Yamaguchi A, Furukawa K, Urano T. (2002). Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett 519: 59-65.
39. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. (1999). Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59: 2041-2044.
40. Walter AO, Seghezzi W, Korver W, Sheung J, Lees E. (2000). The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19: 4906-4916.
41. Yu X, Minter-Dykhouse K, Malureanu LZhao WM, Zhang D, Merkle CJ, Ward IM et al. (2005). Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 37: 401-406.
42. Zhang M, Pickart CM, Coffino P. (2003). Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. EMBO J 22: 1488-1496.
43. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A et al. (1998). Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20: 189-193.